the short history of 50mgs for FBD

Brownstien and Flecha's work comes from Abrahams (his papers are on the optimox site)

Abraham's used  Ghent (now deceased) and Eskin's work. This article says papers publihed in Russia may have lead Ghent and Eskin to start investigating iodine. There is an iodine based drug available in Russia for fibrocystic breasts.

Looks like 50mgs of iodine for fibrocystic breast disease has a history starting with the work of Russian researchers.

http://www.lewrockwell.com/miller/miller20.html

Russian researchers first showed, in 1966, that iodine effectively relieves signs and symptoms of fibrocystic breast disease. Vishniakova and Murav’eva treated 167 women suffering from fibrocystic disease with 50 mg KI during the intermenstrual period and obtained a beneficial healing effect in 71 percent (it is reference 49 here).

and further down......
Then Ghent and coworkers, in a study published in the Canadian Journal of Surgery in 1993, likewise found that iodine relieves signs and symptoms of fibrocystic breast disease in 70 percent of their patients. This report is a composite of three clinical studies, two case series done in Canada in 696 women treated with various types of iodine, and one in Seattle. The Seattle study, done at the Virginia Mason Clinic, is a randomized, double-blind, placebo-controlled trial of 56 women designed to compare 3–5 mg of elemental iodine (I2) to a placebo (an aqueous mixture of brown vegetable dye with quinine). Investigators followed the women for six months and tracked subjective and objective changes in their fibrocystic disease.


and much further in the paper.....
Dr. Guy Abraham, a former professor of obstetrics and gynecology at UCLA, mounted what he calls "The Iodine Project" in 1997 after he read the Ghent paper on iodine for fibrocystic disease. He had his company, Optimox Corp., make Iodoral, the tablet form of Lugol’s solution, and he engaged two family practice physicians, Dr. Jorge Flechas (in 2000) in North Carolina and Dr. David Brownstein (in 2003) in Michigan to carry out clinical studies with it.

Lynn Tweet